234 related articles for article (PubMed ID: 37585218)
1. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
2. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
[TBL] [Abstract][Full Text] [Related]
4. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
Burke AC; Telford DE; Huff MW
Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
[TBL] [Abstract][Full Text] [Related]
5. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
Feng X; Zhang L; Xu S; Shen AZ
Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
7. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
[TBL] [Abstract][Full Text] [Related]
8. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
10. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
12. How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ
Curr Atheroscler Rep; 2024 Mar; 26(3):83-89. PubMed ID: 38294660
[TBL] [Abstract][Full Text] [Related]
13. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
15. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
[TBL] [Abstract][Full Text] [Related]
17. Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention.
Albosta M; Grant JK; Michos ED
Heart Int; 2023; 17(2):27-34. PubMed ID: 38419721
[TBL] [Abstract][Full Text] [Related]
18. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray KK; Nicholls SJ; Li N; Louie MJ; Brennan D; Lincoff AM; Nissen SE;
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):19-28. PubMed ID: 38061370
[TBL] [Abstract][Full Text] [Related]
20. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
